Antihistaminic drug olopatadine downmodulates CCL17/TARC production by keratinocytes and Langerhans cells.
Sugita
Kazunari
K
Kobayashi
Miwa
M
Mori
Tomoko
T
Kabashima
Kenji
K
Nakamura
Motonobu
M
Tokura
Yoshiki
Y
D000818:Animals; D002460:Cell Line; D054414:Chemokine CCL17 / Q000096:biosynthesis*; D003990:Dibenzoxepins / Q000494:pharmacology*; D015536:Down-Regulation / Q000187:drug effects; D039563:Histamine H1 Antagonists, Non-Sedating / Q000494:pharmacology*; D006801:Humans; D066298:In Vitro Techniques; D007371:Interferon-gamma / Q000494:pharmacology; D015603:Keratinocytes / Q000187:drug effects* / Q000276:immunology*; D007801:Langerhans Cells / Q000187:drug effects* / Q000276:immunology*; D051379:Mice; D008807:Mice, Inbred BALB C; D000069605:Olopatadine Hydrochloride; D011994:Recombinant Proteins; D014409:Tumor Necrosis Factor-alpha / Q000494:pharmacology
C106230:CCL17 protein, human; C499538:Ccl17 protein, mouse; D054414:Chemokine CCL17; D003990:Dibenzoxepins; D039563:Histamine H1 Antagonists, Non-Sedating; D011994:Recombinant Proteins; D014409:Tumor Necrosis Factor-alpha; D000069605:Olopatadine Hydrochloride; D007371:Interferon-gamma